Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Aroxybutynin/Atomoxetine Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Aroxybutynin/Atomoxetine: NDA/BLA. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Lysozyme Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Lysozyme: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Amlodipine Benzoate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Amlodipine Benzoate: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Selenious Acid Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Selenious Acid: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Rabimabs Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Rabimabs: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Levilimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Levilimab: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Varnimcabtagene autoleucel Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Varnimcabtagene autoleucel: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Fosdenopterin Hydrobromide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Fosdenopterin Hydrobromide: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
GeGant Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
GeGant: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Coblopasvir hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Coblopasvir hydrochloride: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Ansuvimab-zykl Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Ansuvimab-zykl: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
Brilliant Blue G Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
24 July 2026
Brilliant Blue G: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.